Drug & intervention

osimertinib mesylate

RxCUI 1721559

How to interpret these research links

Connected source records

CureCurrent currently connects this RxNorm drug concept to 5 displayed clinical trials and 9 distinct registered condition labels on this page. The links show what was studied, not whether this drug is effective or approved for those conditions. FDA-label excerpts, when available, refer to specific labeled products and may include route and formulation restrictions.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

What this record represents

PIN · RxNorm

This is an RxNorm PIN drug concept. Its name, formulation details and source identifiers are preserved to distinguish it from other drug records.

What this record does not establish: current marketing availability, therapeutic equivalence, safety, or official approval status. Check an up-to-date product label or a pharmacist for product-specific questions.

Inspect the RxNorm source identifier

Research activity for this drug concept

Published registry records

Study starts and current recruitment statuses across 5 distinct linked trials. This measures registered research activity, not medical effectiveness or FDA approval.

Reported start-year cohortsRegistered start year; the green segment is the subset reported as recruiting in the current snapshot. The current year may be incomplete.

02017

02018

02019

02020

12021

12022

02023

12024

22025

02026

All other statuses Currently recruiting

Current recruiting and other trial statusesCurrent ClinicalTrials.gov status snapshot for linked trials.

RECRUITING2 (40%)

COMPLETED1 (20%)

NOT YET RECRUITING1 (20%)

UNKNOWN1 (20%)

Related drug records

RxNorm name matches

These are other published drug concepts with matching brand or formulation names. They are not necessarily equivalent medicines.

No other matching drug records are currently published. This does not mean they do not exist in RxNorm.

Molecular structure

Verified RxNorm ingredient illustration

Clinical trials5

Recruiting2

Related conditions9

Synonyms4

Clinical trials

5 shown

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerNCT07229729 · 2025-11-24

RECRUITING

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsNCT06829459 · 2025-04-03

RECRUITING

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical SurgeryNCT06530719 · 2024-07-01

NOT_YET_RECRUITING

Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)NCT05085054 · 2022-06-01

UNKNOWN

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerNCT06525246 · 2021-08-06

COMPLETED

Conditions in registry-name-matched drug studies

ClinicalTrials.gov intervention names begin with this ingredient name. These are text matches, not verified RxNorm mappings, evidence of treatment efficacy, or approved indications. Different salts or formulations may be involved.